Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background and Aims: Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness. Approach and Results: We collected cross‐sectional, clinical data including liver biopsies from a derivation (n = 48) and a validation cohort (n = 170) of patients with elevated liver stiffness measurement (LSM ≥ 8.0 kPa). Patients with NAFLD activity scores (NAS) ≥4 were defined as having NASH. Plasma TREM2 levels were significantly elevated in patients with NASH of the derivation cohort, with an area under the receiver operating characteristics curve (AUROC) of 0.92 (95% confidence interval [CI], 0.84–0.99). In the validation cohort, plasma TREM2 level increased approximately two‐fold in patients with NASH, and a strong diagnostic accuracy was confirmed (AUROC, 0.83; 95% CI, 0.77–0.89; p < 0.0001). Plasma TREM2 levels were associated with the individual histologic features of NAS: steatosis, lobular inflammation, and ballooning (p < 0.0001), but only weakly with fibrosis stages. Dual cutoffs for rule‐in and rule‐out were explored: a plasma TREM2 level of ≤38 ng/ml was found to be an optimal NASH rule‐out cutoff (sensitivity 90%; specificity 52%), whereas a plasma TREM2 level of ≥65 ng/ml was an optimal NASH rule‐in cutoff (specificity 89%; sensitivity 54%). Conclusions: Plasma TREM2 is a plausible individual biomarker that can rule‐in or rule‐out the presence of NASH with high accuracy and thus has the potential to reduce the need for liver biopsies and to identify patients who are eligible for clinical trials in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“NAFLD affects approximately 24% of the adult population worldwide.[1] The progression of NAFLD to the more severe form of the disease, NASH, is accompanied by hepatocyte ballooning, hepatic necroinflammation, and fibrosis, and for some it eventually advances to end‐stage liver disease.”
BackgroundSterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×
“We then compared the diagnostic accuracy of different classifications of NASH (NAS > 4, at‐risk NASH, and strict NASH) to other noninvasive test markers involved in NAFLD diagnosis such as FibroScan‐aspartate aminotransferase (FAST) score,[26] Fibrosis‐4 (FIB‐4),[27] Forns index,[28] aspartate aminotransferase (AST)/a…”
MethodEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 1×
“[1] The progression of NAFLD to the more severe form of the disease, NASH, is accompanied by hepatocyte ballooning, hepatic necroinflammation, and fibrosis, and for some it eventually advances to end‐stage liver disease.[2] Currently, liver biopsy is the gold standard to diagnose NASH.”
BackgroundThe role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · cited 13×
“Accordingly, the main outcome was diagnosis of NASH, defined as NAS ≥4,[17] in subjects with an elevated liver stiffness measurement (LSM) (≥8 kPa).”
BackgroundSelf-citationXiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Determination of reliability criteria for liver stiffness evaluation by transient elastography
Boursier, J., Zarski, J.-P., de Ledinghen, V., Rousselet, M.-C., Sturm, N., Lebail, B., Fouchard-Hubert, I., Gallois, Y., Oberti, F., Bertrais, S., et al. (2013) · Hepatology · doi:10.1002/hep.25993 · Cited by 662 · cited 2×
“To further validate the ability of plasma TREM2 levels to discriminate patients with NASH, we performed subgroup analyses and applied two additional classifications: at‐risk NASH, defined as NAS ≥4 and Fibrosis ≥2;[21] and strict NASH according to the SAF‐definition,[23] defined as steatosis ≥1, lobular inflammation ≥…”
Method
Cited by
Wang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00775-1 · Cited by 178
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“…histologic features of NAFLD activity scores (NASs), such as steatosis, lobular in fl ammation, and ballooning, but only weakly with fi brosis stage, suggesting that sTrem2 in plasma may be a noninvasive biomarker that can rule-in or rule-out the presence of MASH with elevated liver stiffness [42].”
Efferocytosis in liver disease
Shi, H., Moore, M. P., Wang, X., & Tabas, I. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2023.100960 · Cited by 30
Cao, C., Liu, W., Guo, X., Weng, S., Chen, Y., Luo, Y., Wang, S., Zhu, B., Liu, Y., & Peng, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460431 · Cited by 16
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
“investigated as a noninvasive diagnostic biomarker in NAFLD patients [49].”
BackgroundSelf-citation
Metadata
- Authors
- Indira Chandran, V., Wernberg, C. W., Lauridsen, M. M., Skytthe, M. K., Bendixen, S. M., Larsen, F. T., Hansen, C. D., Grønkjær, L. L., Siersbæk, M. S., Caterino, T. D., Detlefsen, S., Møller, H. J., Grøntved, L., Ravnskjaer, K., Moestrup, S. K., Thiele, M. S., Krag, A., & Graversen, J. H.
- Venue
- Hepatology
- Published
- 2022-07-14
- Volume
- 77
- Issue
- 2
- Pages
- 558-572
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4283066003
- Cited by
- 62
- References
- 16
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.